Vicor Technologies and the Sudden Cardiac Arrest Association Announce Sponsorship Arrangement

Vicor Technologies, Inc. (OTCBB: VCRT) and the Sudden Cardiac Arrest Association (SCAA) jointly announce the sponsorship of SCAA by Vicor Technologies, Inc. Vicor Technologies is focused on commercializing its diagnostic risk stratification technology, including the PD2i Cardiac Analyzer, a patented device utilized in the risk stratification of patients for Sudden Cardiac Death (SCD).

An organization singularly focused on sudden cardiac arrest, SCAA is dedicated to promoting solutions to prevent sudden cardiac death. SCAA is committed to increasing public awareness of SCD, with the goals of creating more common immediate bystander action, public access to defibrillation (PAD) and access to therapies.

Commenting on the sponsorship, Vicor President and CEO, Mr. David H. Fater, stated, "We are delighted to act as a sponsor of the Sudden Cardiac Arrest Association in their efforts to educate the public about Sudden Cardiac Death. The existence of developing technologies such as ours, which seek to identify the substantial number of patients at high risk of SCD, are in their infancy. A broad understanding of SCD, which is the number one cause of death in the U.S. today, is something we are committed to promoting. Working with organizations such as SCAA is key to this evangelical effort."

Chris Chiames, Executive Director of the Sudden Cardiac Arrest Association, added, "We are excited about having Vicor Technologies become a sponsor. Their efforts in the risk stratification of patients at risk for Sudden Cardiac Death will be an important part of the future for patients. Their assistance in helping SCAA educate the public on sudden cardiac arrest awareness and prevention will help us make a difference in saving lives."

About Sudden Cardiac Death (SCD)

SCD (the leading killer in the U.S. with over 300,000 annual deaths) is a fatal arrhythmic event and is different than a heart attack. A heart attack is analogous to a plumbing problem, where the blood supply to a part of the heart is choked off, leading to the death of that portion of the heart muscle. SCD is theorized to be caused by a breakdown of the normal neurological communication pattern between the heart and brain, more like an electrical problem, which can lead to a rapid, life threatening heart rhythm that is usually fatal within minutes, if untreated. It is swift, unexpected, and often has no advance warning or symptoms.

About Vicor Technologies, Inc.

Vicor's medical device, the PD2i Cardiac Analyzer, is based on a patented, proprietary algorithm. Vicor believes the PD2i Cardiac Analyzer accurately risk stratifies patients who are at high or low risk of suffering a fatal arrhythmic event or SCD within a six-month time frame.

Vicor's PD2i Cardiac Analyzer addresses a significant health care issue involving a patient cohort of at least 12,000,000 patients. This patient cohort is composed of the MADIT-II (Multicenter Automatic Defibrillator Implantation Trial II)/SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) patient population. Many in this patient cohort may need an ICD (Implantable Cardioverter Defibrillator) as life saving therapy. However, recent registry studies have noted that over 70% of implanted ICD's never have an appropriate firing. This over-implantation has led to a substantial and unnecessary medical cost burden. Over-implantation of this patient cohort also puts patients at risk because of the complications that can accompany implantation surgery. There is also the risk of not identifying patients who need this life-saving therapy because current criteria do not provide physicians the ability to accurately risk stratify their patients.

In January 2008, the U.S. Army's Institute of Surgical Research and Vicor signed a Collaborative Research and Development Agreement whereby the PD2i will be utilized to assess severity of injury, and probability of survival, for critically injured combat casualties and critically ill civilian patients. The collaborative effort is envisioned to lead to the development of new comprehensive decision support tools, and or devices that may incorporate the PD2i algorithm alone, or in association with other metrics currently under investigation, with the goal to monitor, assess status and predict outcome in critically injured humans. The study is entitled "Prediction of Injury Severity and Outcome in the Critically Ill Using the Point Correlation Dimension Algorithm."

For more information visit the Vicor Technologies web site www.vicortech.com.

About the Sudden Cardiac Arrest Association

The Sudden Cardiac Arrest Association (SCAA) is an organization singularly focused on sudden cardiac arrest. SCAA identifies and unites survivors, those at risk of sudden cardiac arrest, as well as others who are interested in being advocates on SCAA issues in their communities and beyond. The membership is dedicated to promoting solutions to prevent sudden cardiac death, including increased awareness, immediate bystander action, public access to defibrillation (PAD) and access to therapies such as implantable cardiac defibrillators. (ICDs). SCAA is a nonprofit, tax exempt organization under section 501(c)(3) of the Internal Revenue Code. Contributions to SCAA are tax deductible.

For more information visit the SCAA web site www.suddencardiacarrest.org.

Caution Regarding Forward-Looking Statements

Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to obtain FDA approval of the PD2i Cardiac Analyzer for military and civilian applications, our ability continue to receive financing sufficient to complete the critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 08-10